danvatirsen: Clinical Trials

14 trials of danvatirsen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 active not recruiting, 2 terminated, 1 recruiting. 9 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Completed 6, Active not recruiting 2, Recruiting 1
Phase 26Active not recruiting 2, Completed 2, Terminated 2

Follow danvatirsen: new trials by email Literature Review of danvatirsen trials Research Report on danvatirsen

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Danvatirsen, Danvatirsen + Venetoclax - AML/MDS, Acute Myeloid Leukemia
Phase 1RecruitingMontefiore Medical Center382024-05-082026-10-15
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Danvatirsen, Pembrolizumab - HNSCC
Phase 2TerminatedFlamingo Therapeutics NV692023-05-302026-01-30
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage
Phase 2CompletedMedImmune LLC842019-03-082022-02-24
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Durvalumab, Danvatirsen, Oleclumab - Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1Active not recruitingAstraZeneca1752018-12-272026-05-12
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL
Phase 1CompletedAcerta Pharma BV302018-06-192022-08-15
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
AZD9150, Durvalumab, Cisplatin - Advanced Solid Tumours
Phase 1CompletedAstraZeneca762018-02-072024-08-21
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
AZD9150, Durvalumab - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca112018-01-302019-06-24
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer
Phase 2Active not recruitingAstraZeneca5282017-12-182025-10-27
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center392017-03-022025-05-06
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
AZD4547, MEDI4736, Olaparib - Muscle Invasive Bladder Cancer
Phase 1Active not recruitingAstraZeneca1172016-12-282026-10-01
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
MEDI4736, tremelimumab, AZD9150 - Diffuse Large B-Cell Lymphoma
Phase 1CompletedMedImmune LLC322016-07-132019-02-27
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
AZD9150, MEDI4736, AZD5069 - Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 / Phase 2CompletedAstraZeneca3402015-08-062026-02-11
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
AZD9150 - Ovarian Cancer, Ovarian Neoplasms
Phase 2TerminatedNational Cancer Institute (NCI)12015-04-032017-05-15
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
AZD9150 - Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic
Phase 1CompletedAstraZeneca582013-05-012017-03-06

Conditions studied

Carcinoma, Non-Small-Cell Lung (4)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Ascites (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colorectal Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Turcot syndrome (1)

Sponsors

AstraZeneca (7)  ·  MedImmune LLC (2)  ·  Acerta Pharma BV (1)  ·  Flamingo Therapeutics NV (1)  ·  M.D. Anderson Cancer Center (1)  ·  Montefiore Medical Center (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (12)  ·  Spain (5)  ·  United Kingdom (5)  ·  France (4)  ·  South Korea (4)  ·  Canada (3)  ·  Austria (2)  ·  Belgium (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  Taiwan (2)  ·  Hong Kong (1)  ·  Ireland (1)  ·  Israel (1)

Top investigators

Aditi Shastri, MBBS (1)  ·  Chih-Hsin Yang, MD (1)  ·  David S Hong (1)  ·  Dr David Hong, MD (1)  ·  Frank Neumann, MD (1)  ·  Hendrik-Tobias Arkenau, MD, PhD (1)  ·  Ian Flinn, MD, PhD (1)  ·  John Heymach, M.D, Ph.D (1)  ·  Melissa Johnson, M.D. (1)  ·  Nabil Saba, MD (1)  ·  Sandip Patel, MD (1)  ·  Thomas Powles, MBBS, MRCP, MD (1)  ·  Tim F Greten, M.D. (1)

Results publications

PMID 32203306, PMID 36270753, PMID 37707791, PMID 38351187, PMID 39886125, PMID 41380462

NIH funding

2017 (3), 2015 (2), 2018 (1), 2023 (1)